Authors
Latest:
Enhancing Diversity in CLL Clinical TrialsIra Zackon, MD, explains how clinicians can ensure clinical trial patient populations are more inclusive and minorities are better represented.
Latest:
GigaPath AI Model Shows Promise in Predicting Cancer Mutations and Tumor BurdenThe GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.
Latest:
Next Steps Using Anti-CD19 Therapies in DLBCLThe future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.
Latest:
Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid CancerDuring a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.
Latest:
Further Research Needed to Improve Outcomes in Advanced Ovarian CancerMelissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.
Latest:
Understanding Vorasidenib’s Mechanism of ActionTimothy F. Cloughesy, MD, director of UCLA’s neuro-oncology program and distinguished professor in neurology, discusses the mechanism of action of vorasidenib.
Latest:
Key Takeaways Regarding Use of 45 Gy Novel Radiotherapy in CNS CancersRupesh Kotecha, MD, discusses the key findings from an analysis centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.
Latest:
Roundtable Discussion: Addressing Management of Patients with Metastatic CRPC Following Frontline TreatmentsDuring a Targeted Oncology Case-Based Roundtable event, David I. Quinn, MD, PhD, MBBS leads a discussion on treatment for metastatic castration-resistant prostate cancer following frontline treatment.
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Hematology Workforce Shortage Poses Challenges for Cancer CareSrikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.
Latest:
Peterson on Second-Line Ruxolitinib in Acute GVHDPeterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.
Latest:
Immune Checkpoint to Watch: ICOSDeveloping modern strategies to predict and accurately monitor treatment response remains an important piece of the clinical management puzzle.
Latest:
Keeping Track of FGFR Inhibitor AEs Leads to Optimal OutcomesThis article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.
Latest:
Gergis Explains the Differences Between Acute and Chronic GVHDUsama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each
Latest:
Shining a Light on Sarcoma: Enhancing Awareness for Effective Patient CareAdam C. Berger, MD, FACS, highlights the challenges and advancements in diagnosing and treating sarcoma, a rare and diverse group of cancers originating from mesenchymal tissues.
Latest:
Tailoring Treatments to Better Outcomes in Liver CancerIn season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.
Latest:
The Importance of IMspire150 Data Is Questioned in Melanoma Treatment LandscapeCharles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.
Latest:
O’Brien on the TBCRC049 Trial in HER2+ Breast CancerBarbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with HER2-positive breast cancer and leptomeningeal metastasis.
Latest:
Clinical Pearls for Community Oncologists Treating RCCExpert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.
Latest:
Scordo on Model-Based ATG Dosing in Allo-HCTMichael Scordo, MD, discusses the implications of a new approach to dosing antithymocyte globulin in patients undergoing an allogeneic hematopoietic stem cell transplant.
Latest:
Lenvatinib-Pembrolizumab Duo Delivers Impressive Results in Endometrial CancerThe combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/ChemotherapyJaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.
Latest:
Phase I/II Study Demonstrates Good Efficacy for Gastric CancerShuichi Hironaka, MD, PhD, discusses the efficacy of a phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line treatment of patients with advanced gastric cancer during the 2020 Gastrointestinal Cancers Symposium.
Latest:
AI Tools for Accurate Cancer Diagnosis and Tailored TreatmentAnil Parwani, MD, PhD, discusses how he sees artificial intelligence technology contributing to personalized medicine and helping to tailor treatment plans for individual patients in the future.
Latest:
Achieving Health Equity in Liver CancerPrimary liver cancer death rates vary by region, and much is still to be done in the area of health equity.
Latest:
Biomarkers Employed in CheckMate 739 for Patients With MPMSolange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.
Latest:
Best Therapies for HER2+ Breast Cancer Are Also Best for Brain MetastasesThomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.
Latest:
Beyond the Doctor: How Remote Pharmacists are Revolutionizing Cancer CareAndrea Roman, PharmD, BCOP, discusses findings from a study investigating the benefits of remote oncology pharmacists.
